Based on these findings, it was sound to predict that some of the misfolded mutants of DAT ought to be rescued by pharmacochaperoning with noribogaine, and that childhood dystonia/parkinsonism may be amenable to treatment by pharmacochaperones and/or HSP70 inhibition, which restore folding of the mutated DAT-versions. The gene discussed is SLC6A3; the disease is Parkinson disease.